Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells - Wikidata - wikimedia - TriplyDB

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

http://www.wikidata.org/entity/Q35136002

about

Oncolytic viruses as therapeutic cancer vaccines Clinical use and applications of histone deacetylase inhibitors in multiple myeloma Oncolytic viruses as immunotherapy: progress and remaining challenges Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy HDAC inhibitors and immunotherapy; a double edged sword?Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy Novel insights into the molecular mechanisms of HLA class I abnormalities.Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.Systems biology approach to identification of biomarkers for metastatic progression in cancer.A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women Small-molecular modulators of cancer-associated epigenetic mechanisms.Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.MHC class II regulation by epigenetic agents and microRNAs.Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function.An epigenetic vaccine model active in the prevention and treatment of melanoma Immunotherapy for melanoma: current status and perspectives.Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.Association between putative functional variants in the PSMB9 gene and risk of melanoma--re-analysis of published melanoma genome-wide association studies.Role of gene methylation in antitumor immune response: implication for tumor progression.HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance Restoration of immune response gene induction in trophoblast tumor cells associated with cellular senescence Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.Epigenetics in human melanoma.Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation.Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.Immunotherapy of MHC class I-deficient tumors.Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.Histone deacetylase inhibitors in the generation of the anti-tumour immune response.Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.Combining cancer immunotherapy and targeted therapy.Epigenetics of melanoma: implications for immune-based therapies.Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.

P2860

Q21245758-F8173791-0373-4C20-A2CE-36A836598C79 Q26745930-FB9E7142-2DC6-4F4C-A5FD-2DEB55F13799 Q26745942-68576A88-E14A-4FE0-93E9-20457D46A9F6 Q26769977-A1D47898-DA93-466E-ABB3-D34CB5A92BFC Q26783032-6EE62758-2A56-449F-9C95-43CE3859F024 Q26853102-7B78560A-48D4-4495-927D-AC90D2DAA3CD Q27691330-48A74257-E52C-4077-A65C-A4FCE29CAA94 Q28076473-0262D7D4-8CB7-4375-A25E-200AF63440AE Q30318252-FF3C2BF0-6853-4F0B-8ED7-8E246E4BA415 Q30318613-3CC4A45A-5E71-4E90-A083-1FFB690B40B6 Q33369631-DE574BEF-784E-4E4B-9A22-B140EF9543C7 Q33436058-E97A42D8-BDE0-442D-890C-61A52CBFA053 Q33570005-D0191332-A076-4FDD-8377-59DC5B7BA2C5 Q33720183-7E60F2DD-DF93-46E7-85EC-D607E856387E Q33980682-93A5442D-5C2A-4935-AA9A-161B12173391 Q34425118-602B0FC2-4770-40CC-ADD1-9FC50E38A21F Q34628002-2B9C30D0-1051-4445-93C0-E359E5728522 Q34652570-37A28505-9FA3-48F8-914D-EDE7D5B1F6E9 Q35092329-1D4C35E6-2B43-407A-933E-B067005756F4 Q36104946-22F659D0-8F88-4490-A41E-0616B062DF85 Q36440002-59A19E70-5FB4-42B5-97A1-1398F733F233 Q36453216-B5D935D2-158A-45BF-896D-CC026D28C552 Q37022306-4331E830-2D0E-4480-9882-A97794FF1B9E Q37040983-520DA036-228F-4143-9D09-BED255E7C3A8 Q37132658-8A581737-4395-4887-B8CE-8ADC473BED86 Q37287152-337687A1-4CD5-4851-BC86-951520A6EB34 Q37317571-8465AE8C-713D-4322-8DCC-0F4F4B00F83E Q37426386-6A5E7205-DF5E-4DF2-BA4D-2707C5DB32E9 Q37531849-7EDD94E2-D757-4B2C-90CC-FBCAB250816B Q37554202-0E3B9CD1-AB75-45E4-A4BB-43B31B6AD19B Q37773238-5FB52CEE-024A-4AD9-8FE7-5FBB726411FA Q37808218-EA20EEA0-A03E-43B8-83EF-72E855959204 Q37821337-589F51A3-434D-4716-B26F-AD13B3C253AA Q37863518-735C336D-375A-459C-B328-0A3A09D2D3CC Q37953826-419C7117-3EFA-438A-B3B8-8B2D46BEE5A0 Q37959304-BD21E731-B6FA-4A77-B549-D87D1CF0C951 Q38029543-98DE8D47-7F8C-4E28-87BA-AA02EF06CA46 Q38096565-322C7708-C9E3-4394-8CFC-D37463DED14D Q38148588-9715B45C-5F80-426B-AF9C-E9253CAEA09A Q38159805-3270FFA3-7BC6-4633-9C76-0827F11D5741

P2860

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

http://www.wikidata.org/entity/Q35136002

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Histone deacetylase inhibitors ...... presentation by melanoma cells

@ast

Histone deacetylase inhibitors ...... presentation by melanoma cells

@en

type

label

Histone deacetylase inhibitors ...... presentation by melanoma cells

@ast

Histone deacetylase inhibitors ...... presentation by melanoma cells

@en

prefLabel

Histone deacetylase inhibitors ...... presentation by melanoma cells

@ast

Histone deacetylase inhibitors ...... presentation by melanoma cells

@en

P1433

Q35136002-92FDC0B6-35C5-4470-BB12-DFDCA32BB150

P1476

Q35136002-89D635FC-FAA2-4C01-9489-3B1705515D64

P2093

Q35136002-04497312-8200-48EB-83B0-F53C0AFEB3A4

Q35136002-26C6514B-D26F-4510-9FE6-CD56281D181E

Q35136002-85D90731-EF22-4CD6-9F62-8968A10F2F27

P2860

Q35136002-042BC0AA-9863-47EB-B977-D6C0A44ADFA2

Q35136002-05FBCF8B-82A1-4855-83B2-EDC6E80FC3FD

Q35136002-0D68F0EA-6D22-4FB2-811C-641ED3D2190F

Q35136002-0EF9C35C-495D-4996-B4F1-045243D49E5A

Q35136002-0FBEF6DC-D7AB-4166-B6A7-8FBD0F67A0E6

Q35136002-0FCE2CC6-60C0-4F98-AD54-B03944DB3FCD

Q35136002-151B2974-88F6-47E5-B3F1-8367698C5430

Q35136002-17818326-6A9B-404D-BBAB-E7D61848D635

Q35136002-2311A785-376C-497F-A868-AD50EF9B0CE1

Q35136002-2641CC6E-371C-447A-85C8-9738074E1E99

P2888

Q35136002-61F2C284-7F2A-4C33-BA57-235B7E25C009

P304

Q35136002-DE933C33-E157-4E87-86C8-39338BBB97F2

P31

Q35136002-A56925AF-3645-45A0-B186-9C1C56C7F909

P356

Q35136002-C6D938E2-6A34-4CD4-BDEC-DBEC245D6585

P433

Q35136002-3F497746-AE39-4FC9-8DE4-A20B61A5E579

P478

Q35136002-27574228-4F7B-4F14-8C77-A8335D1E13F1

P577

Q35136002-DDD76907-CF97-41AD-A9B1-DA8D9264690A

P5875

Q35136002-CC0F5C52-1143-464E-8DFE-84E29FD2DF97

P698

Q35136002-E9609B26-20E3-47C0-9001-6BB2009C435F

P932

Q35136002-37E8C912-00BE-4F27-BA65-974E3D251839

P356

S00262-007-0402-4

P1433

Cancer Immunology, Immunotherapy

P1476

Histone deacetylase inhibitors ...... presentation by melanoma cells

@en

P2093

A Nazmul H Khan

http://www.w3.org/2001/XMLSchema#string

Christopher J Gregorie

http://www.w3.org/2001/XMLSchema#string

Thomas B Tomasi

http://www.w3.org/2001/XMLSchema#string

P2860

Translating the Histone Code

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid

Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation

Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells

T cell receptor antagonist peptides induce positive selection

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.

Antigen-processing machinery breakdown and tumor growth.

Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation.

Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.

P2888

s00262-007-0402-4

P304

647-654

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-007-0402-4

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5800506

http://www.w3.org/2001/XMLSchema#string

P698

18046553

http://www.w3.org/2001/XMLSchema#string

P932

3146348

http://www.w3.org/2001/XMLSchema#string